Suri Anish 4
4 · Cue Biopharma, Inc. · Filed Mar 29, 2022
Insider Transaction Report
Form 4
Suri Anish
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2022-03-25+21,333→ 21,333 totalExercise: $5.01Exp: 2032-03-24→ Common Stock (21,333 underlying) - Award
Stock Option (right to buy)
2022-02-09+82,000→ 82,000 totalExercise: $6.91Exp: 2032-02-08→ Common Stock (82,000 underlying)
Footnotes (2)
- [F1]1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 9, 2022.
- [F2]2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.